Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Anticipating designer drug-resistant cancer cells.

Drug discovery today - 1 Jul 2015

Frangione Mark L, Lockhart John H, Morton Daniel T, Pava Libia M, Blanck George

Abstract excerpt

Successful use of anticancer designer drugs is likely to depend on simultaneous combinations of these drugs to minimize the development of resistant cancer cells. Considering the knowledge base of cancer signaling pathways, mechanisms of designer drug resistance should be anticipated, and early c...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Databases, Protein
Share to Drug Design
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Molecular Diagnostic Techniques

Share to Molecular Targeted Therapy

Share to Precision Medicine

Share to Predictive Value of Tests

Share to Software

Source

Identifiers

PMID: 25697478
DOI: 10.1016/j.drudis.2015.02.005

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-25697478-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Anticipating designer drug-resistant cancer cells.PMID 25697478Read ↗

A Methodological Workflow to Analyze Synthetic Lethality and Drug Synergism in Cancer Cells.Semantic proximity Read ↗

Targeting pan-essential pathways in cancer with cytotoxic chemotherapy: challenges and opportunitiesSemantic proximity Read ↗

KRAS: Druggable at Last.Semantic proximity Read ↗

Durability of Kinase-Directed Therapies—A Network Perspective on Response and ResistanceSemantic proximity Read ↗

Overcoming Cancer Drug Resistance Utilizing PROTAC TechnologySemantic proximity Read ↗

Identifying chemogenetic interactions from CRISPR screens with drugZSemantic proximity Read ↗

Selectivity filters to edit out deleterious side effects in kinase inhibitors.Semantic proximity Read ↗

Identification of synthetic chemosensitivity genes paired with BRAF for BRAF/MAPK inhibitors.Semantic proximity Read ↗

Designed Multiple Ligands for Cancer TherapySemantic proximity Read ↗

A cell-based high-throughput screen to identify synergistic TRAIL sensitizersSemantic proximity Read ↗

Combinatorial drug screening identifies compensatory pathway interactions and adaptive resistance mechanismsSemantic proximity Read ↗

Challenges and opportunities for drug repurposing in cancers based on synthetic lethality induced by tumor suppressor gene mutationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.